Capricor Therapeutics' stock surged 71% to $7.19 on Friday, Aug. 14, 2026, after the company announced plans to amend its FDA approval application for its Duchenne muscular dystrophy (DMD) cell therapy, deramiocel, following a negative FDA advisory committee vote on efficacy.
The FDA advisory committee voted 9–3 against recommending approval of deramiocel for DMD cardiomyopathy, citing concerns about the analysis of trial endpoints and the trial population's baseline heart function.
Capricor plans to submit an amendment focused on the primary endpoint of upper limb function from the Phase 3 HOPE‑3 trial, including 24‑month data from the open‑label extension and additional analyses, which the FDA has indicated it is willing to review.
The FDA’s action date for the existing application remains Aug. 22, 2026; after the amendment is submitted, the PDUFA date is expected to be extended by about three months, consistent with treatment of the resubmission as a major amendment.
Shares have recouped some of their steep earlier losses but remain well below pre‑setback levels near $20, reflecting investor relief over a potential regulatory path forward despite the prior adcom setback.
Sources:
Capricor soars on plan to amend DMD filing after adcomm setback
Capricor shares soar as potential FDA lifeline revives Duchenne drug hopes
FDA AdCom shuns Capricor's DMD cell therapy amid data dispute
Capricor CEO won't rule out legal action against FDA after negative ...
FDA adcom declines to recommend Capricor's Duchenne drug | STAT
CAPR Plunged About 64% After FDA Briefing Docs Hit. AdCom Is ...
Capricor shares sink as US FDA declines to approve cell therapy
Capricor shares turn red as FDA plans deramiocel ...
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor thrown for another loop as FDA sets adcomm ...
Capricor Therapeutics Announces Establishment of New ...
CAPR Stock Eyes Worst Week Ever After FDA Panel Blow ...
Capricor surges on amended plans for lead drug (CAPR:NASDAQ)